KURA

Stats

Summary

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.

Market Cap: 1.73 Billion

Primary Exchange: NASDAQ

Website: https://www.kuraoncology.com/

Shares Outstanding: 76.1 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.910454455802416

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1049 trading days

From: 2020-12-11 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor